Invent The Future - UC Davis Health System

More documents

Recommendations

Info

PERCENT SURVIVAL 100 80 60 40 20 Latent Period (Increasing obstruction Myocardial overload) Onset Severe Symptoms Prolonged latent period - morbidity & mortality very low Symptomatic aortic stenosis - Cardinal symptoms Angina • Syncope • Heart failure Onset of symptoms - Outlook changes dramatically Average survival 2 - 3 years - High risk of sudden death Management decisions based on these data Asymptomatic - Conservative treatment Symptomatic - Aortic Valve Replacement Angina Syncope Failure 2 3 5 AV. SURVIVAL YEARS Average age death (males) 40 50 60 63 70 80 AGE, YEARS
TAVI Trans femoral High Risk TF 1:1 Randomization VS PARTNER Study Design ASSESSMENT: Transfemoral Access Surgical AVR Symptomatic Severe Aortic Stenosis TAVI Trans femoral ASSESSMENT: High Risk AVR Candidate 3105 Total Patients Screened High Risk TA 1:1 Randomization Surgical AVR Primary Endpoint: All Cause Mortality (1 yr) (Non-inferiority) VS Total = 1058 patients n= 700 High Risk 2 Parallel Trials: Inoperable n=358 Individually Powered TAVI Trans femoral 1:1 Randomization VS ASSESSMENT: Transfemoral Access Standard <strong>The</strong>rapy (usually BAV) Not In Study Primary Endpoint: All Cause Mortality over length of trial (Superiority)
Page 1 and 2: TAVR: It’s a Career, Not Just a P
Page 3 and 4: Before You Start • Do you have a
Page 5: - Etiology Calcific degenerative A
Page 9 and 10: 30% Absolute Reduction in Cardiovas
Page 11 and 12: Valve Size Selection • The SAPIEN
Page 13 and 14: 23 mm or 26 mm Valve? • The prima
Page 15: Prepare the Patient • RIJ large s
Page 20 and 21: 9000TFX Edwards SAPIEN Transcathete
Page 22 and 23: Edwards SAPIEN Valve Model 9000TFX
Page 24 and 25: RetroFlex 3 Delivery System Tapered
Page 27 and 28: Rapid Ventricular Pacing: Test Run
Page 29 and 30: Crossing Native Valve • Flex cath
Page 32: Edwards SAPIEN Valve Valve Foreshor
Page 35 and 36: •Reinsert introducer into sheath
Page 37 and 38: CCU/CTICU • Systolic blood pressu
Page 39 and 40: Registry • Mandatory reporting of
Page 41 and 42: Boston Scientific - Lotus TM Valve
Page 43: Thanks

Invent The Future - UC Davis Health System

Create successful ePaper yourself

Delete template?

Save as template?